Next-generation sequencing has transformed genomics research and is progressively transforming clinical diagnostics in ways that were anticipated a decade ago but that the pace of technology cost reduction and clinical validation are now making routine rather than experimental. The sequencing of a human genome -- which cost three billion dollars and required a decade of coordinated international effort for the Human Genome Project -- now costs less than two hundred dollars in reagent and compute expenses on the most cost-efficient platforms and can be completed in a day. This cost and speed trajectory has enabled genomic sequencing to move from a tool used exclusively in well-funded research institutions to a clinical tool deployed in hospital molecular pathology laboratories, oncology programmes, and reproductive medicine settings where the genomic information that sequencing provides directly informs patient care decisions.
The commercial structure of the NGS market has historically been defined by Illumina's dominant position in short-read sequencing instruments and consumables. Illumina's technology -- which sequences DNA by synthesising complementary strands while detecting the fluorescent signals from incorporated nucleotides -- has been the platform of choice for the vast majority of genomics research and clinical sequencing applications over the past fifteen years, and Illumina has maintained and grown its market share through a combination of continuous instrument and chemistry improvements, aggressive pricing of consumable reagents that creates a recurring revenue stream from the installed base, and deep integration with the bioinformatics and laboratory information management software that customers use to analyse and manage sequencing data. The HiSeq, NovaSeq, and NextSeq instrument families have served the full range of throughput needs from single-gene tests to whole-genome population studies, and Illumina's library preparation and sequencing reagent consumables generate the majority of its revenue and operating profit.
Long-Read Sequencing: The Technology Challenge to Illumina's Position
The fundamental limitation of short-read sequencing -- that it reads DNA in fragments of one hundred to three hundred base pairs that must then be computationally assembled into a full genome sequence -- creates problems in regions of the genome where repetitive sequences, structural variants, and complex rearrangements prevent accurate assembly from short reads alone. Long-read sequencing technologies that can read DNA fragments of thousands to hundreds of thousands of base pairs in a single read -- which Pacific Biosciences (PacBio) and Oxford Nanopore Technologies have commercialised through two distinct technical approaches -- provide the ability to sequence directly through these complex genomic regions and to detect structural variants, epigenetic modifications, and phasing of genetic variants on the same chromosome that short-read sequencing cannot resolve.
PacBio's HiFi long-read sequencing technology -- which generates highly accurate long reads by sequencing the same DNA molecule multiple times in a circular template -- has demonstrated accuracy rates that approach or match short-read sequencing for individual base calls while providing read lengths of fifteen to twenty kilobases that are orders of magnitude longer than Illumina reads. The Revio instrument that PacBio launched in 2023 substantially improved the throughput and cost efficiency of HiFi sequencing and has been adopted for clinical-grade whole genome sequencing at leading academic medical centres and genomic medicine programmes. The clinical applications where long-read whole genome sequencing is demonstrating superior diagnostic yield over short-read equivalents -- rare disease diagnosis, cancer genome characterisation, structural variant detection -- are precisely the high-value clinical sequencing applications where the additional cost of long-read sequencing is justified by improved diagnostic performance.
Oxford Nanopore's technology -- which sequences DNA by detecting changes in electrical current as DNA passes through a nanopore protein embedded in a membrane -- provides the longest read lengths of any commercial sequencing platform and uniquely can detect epigenetic modifications (DNA methylation) directly in the base-calling step without requiring separate bisulfite treatment. The MinION sequencer, which is the size of a USB stick and can run on a laptop, has created a portable sequencing capability that has been deployed in field settings including infectious disease outbreak surveillance, agricultural pathogen detection, and environmental monitoring. Oxford Nanopore's accuracy limitations -- single-pass raw read accuracy that is lower than PacBio HiFi or Illumina short reads -- have historically been a barrier to clinical adoption, but successive chemistry and basecalling improvements have narrowed this gap substantially and the platform is now in clinical evaluation for applications where its unique capabilities (ultra-long reads, direct epigenetic detection, real-time analysis) outweigh its accuracy limitations.
Illumina's Response and the Competitive Equilibrium
Illumina's response to the long-read competition has been both defensive and offensive. Defensively, the company has continued to improve the accuracy and throughput of its short-read platforms -- the NovaSeq X series launched in 2023 offers the highest throughput and lowest cost per gigabase of any short-read platform and resets the cost floor for large-scale genomic sequencing at a level that long-read platforms cannot currently match. The NovaSeq X's cost structure enables population-scale whole genome sequencing projects that are beyond the economics of long-read alternatives, maintaining Illumina's competitive position in the high-throughput research and biobank sequencing applications where read length is less critical than throughput and cost efficiency.
The competitive equilibrium that is emerging in clinical sequencing is a complementary rather than a winner-take-all dynamic: short-read sequencing remains the preferred platform for standard clinical applications including oncology panel testing, carrier screening, and population-scale research where cost and throughput are the primary competitive dimensions; long-read sequencing is capturing the clinical applications where its read length and structural variant capabilities provide diagnostic advantages that short-read cannot match; and the Oxford Nanopore platform is finding a distinct niche in applications that require portable, real-time sequencing rather than the highest accuracy. This complementary dynamic benefits PacBio and Oxford Nanopore by creating durable market positions in applications where Illumina's cost advantage is less relevant, while Illumina retains the largest share of the overall sequencing market through its cost and throughput dominance in mainstream applications.
Bioinformatics and Data Infrastructure: The Hidden Competitive Dimension
The sequencing instrument and consumable market cannot be evaluated in isolation from the bioinformatics and data management infrastructure that converts raw sequencing output into clinically actionable genomic information. The volume of data generated by high-throughput sequencing instruments -- a single NovaSeq X run generates multiple terabytes of raw sequencing data -- requires substantial computational infrastructure and sophisticated bioinformatics pipelines that align reads to reference genomes, identify variants, annotate their clinical significance, and present results in formats that clinical users can interpret and act on. The bioinformatics capability required to operate a clinical sequencing programme is a significant operational investment that is separate from the instrument acquisition cost and that represents a barrier to entry for smaller laboratories and healthcare systems that lack the computational and bioinformatics expertise to build and maintain these pipelines internally.
The commercial response from sequencing instrument vendors has been to bundle bioinformatics software and cloud computing access with instrument platforms, creating integrated sequencing-to-result workflows that reduce the bioinformatics barrier for clinical laboratory customers. Illumina's DRAGEN analysis pipeline and BaseSpace genomics cloud platform, PacBio's SMRT Link analysis software, and Oxford Nanopore's EPI2ME cloud analysis platform each provide varying degrees of integrated analysis capability that allows clinical laboratories to operate sequencing programmes without building entirely bespoke bioinformatics infrastructure. Third-party bioinformatics vendors including Illumina-acquired Edico Genome, DNAnexus, and Seven Bridges are providing cloud-based genomic analysis platforms that are instrument-agnostic and that serve laboratories running multiple sequencing platforms from different vendors. The bioinformatics layer is increasingly a battleground for clinical genomics market share that is as important as the instrument hardware and chemistry in determining which sequencing platforms are adopted by clinical laboratories making long-term infrastructure investments.
Top 10 Companies in This Space
- Illumina Inc -- US genomics instrument leader, dominant short-read sequencing platform across research and clinical genomics globally
- Pacific Biosciences (PacBio) -- US long-read sequencing company, HiFi Revio platform for clinical-grade long-read genome sequencing
- Oxford Nanopore Technologies -- UK sequencing company, nanopore-based long-read and ultra-long-read sequencing with portable MinION platform
- Element Biosciences -- US NGS startup, AVITI short-read sequencer targeting mid-throughput labs with competitive reagent economics
- Ultima Genomics -- US sequencing startup, ultra-low-cost whole genome sequencing platform targeting large-scale population and clinical sequencing
- Singular Genomics -- US NGS startup, G4 sequencer for spatial and single-cell sequencing applications in research settings
- 10x Genomics -- US spatial and single-cell genomics company, library preparation and spatial transcriptomics tools that run on Illumina and other platforms
- QIAGEN (NGS) -- German life science tools company, NGS library preparation reagents and bioinformatics (CLC Genomics Workbench) for clinical and research genomics
- Agilent Technologies (Genomics) -- US life science tools company, target enrichment panels and library preparation reagents for clinical NGS applications
- MGI Tech (BGI Group) -- Chinese sequencing company, DNBSEQ short-read platform competing on price in Asian and European research sequencing markets
Our Take
The NGS instrument market is entering the most competitive phase of its commercial history as PacBio's HiFi platform and Oxford Nanopore's improving accuracy erode the clinical application monopoly that Illumina has held through its short-read accuracy and throughput advantages. The clinical genome sequencing market is large enough and growing fast enough to support multiple platform winners, and the complementary positioning of short-read and long-read technologies means this is not a zero-sum competition -- PacBio can grow its clinical business substantially without taking share from Illumina's core applications. The more interesting competitive threat to Illumina comes from Element Biosciences and Ultima Genomics, which are targeting the mid-throughput and high-throughput short-read market respectively with instruments that offer competitive performance at lower reagent costs than Illumina's consumable pricing. The consumable pricing model that generates the majority of Illumina's recurring revenue is the most vulnerable element of its market position, and the competitive pressure on reagent costs from these challengers is a structural headwind for Illumina's margins even as the overall sequencing market grows. -- Priya Nair, MarketsNXT